KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Receivables (2016 - 2025)

Historic Receivables for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $84.5 million.

  • Travere Therapeutics' Receivables rose 20505.42% to $84.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.5 million, marking a year-over-year increase of 20505.42%. This contributed to the annual value of $29.4 million for FY2024, which is 1410.84% up from last year.
  • As of Q3 2025, Travere Therapeutics' Receivables stood at $84.5 million, which was up 20505.42% from $40.2 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Receivables peaked at $84.5 million during Q3 2025, and registered a low of $11.9 million during Q2 2021.
  • For the 5-year period, Travere Therapeutics' Receivables averaged around $25.3 million, with its median value being $22.9 million (2023).
  • Its Receivables has fluctuated over the past 5 years, first crashed by 2762.43% in 2021, then surged by 20505.42% in 2025.
  • Over the past 5 years, Travere Therapeutics' Receivables (Quarter) stood at $16.8 million in 2021, then grew by 10.3% to $18.5 million in 2022, then surged by 39.0% to $25.8 million in 2023, then increased by 14.11% to $29.4 million in 2024, then surged by 187.26% to $84.5 million in 2025.
  • Its Receivables was $84.5 million in Q3 2025, compared to $40.2 million in Q2 2025 and $36.5 million in Q1 2025.